185 related articles for article (PubMed ID: 15364638)
21. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.
Knisely JS; Wunsch MJ; Cropsey KL; Campbell ED
J Subst Abuse Treat; 2008 Dec; 35(4):380-6. PubMed ID: 18657935
[TBL] [Abstract][Full Text] [Related]
22. The promotion and marketing of oxycontin: commercial triumph, public health tragedy.
Van Zee A
Am J Public Health; 2009 Feb; 99(2):221-7. PubMed ID: 18799767
[TBL] [Abstract][Full Text] [Related]
23. The marketing of OxyContin®: A cautionary tale.
Egilman DS; Collins GDYCB; Falender J; Shembo N; Keegan C; Tohan S
Indian J Med Ethics; 2019; 4(3):183-193. PubMed ID: 31727614
[TBL] [Abstract][Full Text] [Related]
24. Oxycontin--misuse and abuse.
Suleman R; Abourjaily H; Rosenberg M
J Mass Dent Soc; 2002; 51(2):56-8. PubMed ID: 12108125
[No Abstract] [Full Text] [Related]
25. Major increases in opioid analgesic abuse in the United States: concerns and strategies.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Feb; 81(2):103-7. PubMed ID: 16023304
[TBL] [Abstract][Full Text] [Related]
26. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse.
Inciardi JA; Surratt HL; Stivers Y; Cicero TJ
J Opioid Manag; 2009; 5(2):81-7. PubMed ID: 19507804
[TBL] [Abstract][Full Text] [Related]
27. A flood of opioids, a rising tide of deaths.
Okie S
N Engl J Med; 2010 Nov; 363(21):1981-5. PubMed ID: 21083382
[No Abstract] [Full Text] [Related]
28. 'Not an appropriate use'. Did the makers of OxyContin push too hard?
Spake A
US News World Rep; 2001 Jul; 131(1):26. PubMed ID: 11447650
[No Abstract] [Full Text] [Related]
29. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
30. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers.
Smith MY; Irish W; Wang J; Haddox JD; Dart RC
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1050-9. PubMed ID: 18803336
[TBL] [Abstract][Full Text] [Related]
31. The Diversion of Ultram, Ultracet, and generic tramadol HCL.
Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE
J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220
[TBL] [Abstract][Full Text] [Related]
32. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
33. Prescription OxyContin abuse among patients entering addiction treatment.
Carise D; Dugosh KL; McLellan AT; Camilleri A; Woody GE; Lynch KG
Am J Psychiatry; 2007 Nov; 164(11):1750-6. PubMed ID: 17974941
[TBL] [Abstract][Full Text] [Related]
34. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.
Hays L; Kirsh KL; Passik SD
J Natl Compr Canc Netw; 2003 Jul; 1(3):423-8. PubMed ID: 19761073
[TBL] [Abstract][Full Text] [Related]
35. The danger of imperfect regulation: OxyContin use in the United States and Canada.
Lexchin J; Kohler JC
Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088
[TBL] [Abstract][Full Text] [Related]
36. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future.
Loder E
Cephalalgia; 2006 Feb; 26(2):89-97. PubMed ID: 16426261
[TBL] [Abstract][Full Text] [Related]
37. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
38. FDA actions to prevent prescription drug abuse.
Jeske AH
Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
[No Abstract] [Full Text] [Related]
39. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
Drug Enforcement Administration (DEA), Justice
Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
[TBL] [Abstract][Full Text] [Related]
40. Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.
Katz MH; Kotabe S
Med Care; 2008 Sep; 46(9):1002. PubMed ID: 18725857
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
